Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Sequential lysosome-microtubule targeted transformable nanosystem for long-lasting photodynamic-based multimodal therapy of breast cancer.

Created on 07 Sep 2026

Authors

Ruyi Lin, Li Xia, Yatong Zhang, Jia Yan, Yujun Song, Yufan Du, Yuan Huang, Jing Wang, Hao Wang, Huile Gao, Fan Tong

Published in

Journal of controlled release : official journal of the Controlled Release Society. Pages 115336. Sep 06, 2026. Epub Sep 06, 2026.

Abstract

Subcellular organelle-targeted strategies hold great promise in cancer therapy. Peptide nanofibers can induce lysosomal membrane permeabilization (LMP) and microtubule disruption, yet their in vivo delivery remains challenging. Here, we report a matrix metalloproteinase-2 (MMP-2)-responsive shape transformable nanosystem (CpA) that self-assembles from the amphiphilic conjugate Ce6-pep-iABS, comprising the photosensitizer chlorin e6 (Ce6) and the carbonic anhydrase IX (CA IX) inhibitor 4-(2-aminoethyl) benzenesulfonamide (ABS) linked via an MMP-2-cleavable peptide. Upon reaching tumors, CpA transforms from spherical nanoparticles into nanofibers, enabling deep penetration and long-term retention in tumor. The released ABS segments continuously inhibit CA IX to reverse extracellular acidosis and alleviate immunosuppression. Crucially, the transformed nanofibers exhibit enhanced cellular uptake and induce sequential LMP and microtubule disruption, which synergizes with photodynamic therapy (PDT) to amplify immunogenic cell death (ICD), activate robust antitumor immunity, and establish long-lasting immunological memory. This synergistic effect significantly inhibits tumor growth and prevents tumor recurrence and metastasis, presenting an innovative paradigm for multimodal cancer therapy by integrating sequential organelle targeting, tumor microenvironment modulation, and intensified PDT.

PMID:
42702252
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement